Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
Online First
Web Exclusives
All Web Exclusives
Videos
Monthly Minutes
Conversations on CCA
Interview with the Innovators
Press Releases
CCA Summit
Cholangiocarcinoma Summit
Cholangiocarcinoma
Immune-Related AEs in the TOPAZ-1 Study of Durvalumab plus GemCis in Advanced BTC
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
— January 4, 2023
Immune-related adverse events in the TOPAZ-1 trial were more common in the durvalumab arm, had a variable time to onset, and were associated with improved overall survival.
Read More
2022 Year in Review: Cholangiocarcinoma
By
Richard Kim, MD
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
— January 4, 2023
In 2022, the COVID-19 pandemic continued to impact the practice of medicine and dissemination of treatment advances presented in scientific forums. Adapting to the changes, societies such as the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, and European Society for Medical Oncology have adopted virtual and hybrid formats that deliver cutting-edge research in the advancement of oncology care. Recognizing the challenges of the virtual and hybrid formats in terms of reach and impact, we are bringing the
Year in Review
series that seeks to disseminate key information on treatment advances to clinicians in a timely and effective manner.
Read More
Results from the ABC-06 Trial: Tumor Markers in Advanced BTCs Treated with Second-Line Active Symptom Control Alone or in Combination with FOLFOX
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
— January 4, 2023
Analysis of the phase 3 ABC-06 trial revealed limited prognostic utility of the tumor marker CA19.9 after initiation of FOLFOX.
Read More
Interim Analysis of the FIDES-01 Study
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
— January 4, 2023
Derazantinib was found to provide clinical benefit in patients with advanced intrahepatic cholangiocarcinoma harboring
FGFR2
mutations or amplifications.
Read More
PROs from the TOPAZ-1 Study Evaluating Durvalumab plus GemCis in Advanced BTCs
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
— January 4, 2023
Assessment of patient-reported outcomes revealed no clinically meaningful detriment occurred with the addition of durvalumab to gemcitabine/cisplatin in advanced biliary tract cancers.
Read More
Results from the Regional Subgroup Analysis of the TOPAZ-1 Study Evaluating Durvalumab plus GemCis in Advanced BTCs
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
— January 4, 2023
Despite differences in baseline prognostic characteristics identified by the regional analysis of the TOPAZ-1 study, outcomes between the regions were generally similar.
Read More
Preliminary Results from the FIDES-01 Trial: Derazantinib as a Second-Line Treatment for iCCA with FGFR2 Alterations
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
— January 4, 2023
The FIDES-01 clinical trial showed encouraging preliminary results for derazantinib as a second-line treatment in patients with intrahepatic cholangiocarcinoma harboring
FGFR2
alterations.
Read More
Results from the Phase 2 NEO-GAP Trial: Neoadjuvant Gemcitabine/Cisplatin/Nab-Paclitaxel for Resectable High-Risk iCCA
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
— January 4, 2023
NEO-GAP investigators found neoadjuvant gemcitabine/cisplatin/nab-paclitaxel combination to be feasible and safe prior to curative-intent surgical resection in patients with intrahepatic cholangiocarcinoma.
Read More
Early Data from the ReFocus Trial
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
— January 4, 2023
Early data from the ReFocus trial indicated that RLY-4008 may be an effective new treatment for patients with cholangiocarcinoma harboring
FGFR2
fusions or rearrangements.
Read More
TOPAZ-1 Trial Subanalysis: Outcomes by Primary Tumor Location in Advanced BTCs
Cholangiocarcinoma
2022 Year in Review: Cholangiocarcinoma
— January 4, 2023
Subanalysis of the phase 3 TOPAZ-1 trial found that durvalumab plus gemcitabine/cisplatin showed efficacy as a treatment regimen in patients with biliary tract cancer regardless of primary tumor location.
Read More
Page 5 of 14
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of CCA News
Read Issue
Home
Issues
Latest Issue
Issue Archive
Special Issues
Online First
Web Exclusives
All Web Exclusives
Videos
Monthly Minutes
Conversations on CCA
Interview with the Innovators
Press Releases
CCA Summit
Cholangiocarcinoma Summit
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
CCA News
Print Edition
CCA News
Weekly e‑Newsletter
-- Please Select Country --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
CCA News
's
Privacy Policy
, and
CCA News
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION